327036-89-5
327036-89-5 結(jié)構(gòu)式
基本信息
TDZD-8
TDZD 8
TDZD8
NP 01139
4-苯甲基-2-甲基-1,2,4-噻二唑烷-3,5-二酮
4-苯甲基-2-甲基-1,2,4-噻二唑烷-3,5-二酮 100MG
TDZD-8/TDZD8
TDZD-8, >=98%
GSK-3InhibitorI,TDZD-8
1,2,4-Thiadiazolidine-3,5-dione,2-Methyl-4-(phenylMethyl)-
4-Benzyl-2-methyl-[1,2,4]thiadiazolidine-3,5-dione TDZD-8
物理化學(xué)性質(zhì)
應(yīng)用領(lǐng)域
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | B4436 | 4-苯甲基-2-甲基-1,2,4-噻二唑烷-3,5-二酮 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | 327036-89-5 | 5mg | 160元 |
| 2024/11/08 | S2926 | 4-BENZYL-2-METHYL-1,2,4-THIADIAZOLIDINE-3,5-DIONE TDZD-8 | 327036-89-5 | 5mg | 1181.41元 |
| 2024/11/08 | B4436 | 4-苯甲基-2-甲基-1,2,4-噻二唑烷-3,5-二酮 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | 327036-89-5 | 25mg | 620元 |
常見問題列表
| Target | Value |
| GSK-3β | 2 μM |
TDZD-8作為非ATP競(jìng)爭(zhēng)性抑制劑或與GS-1結(jié)合。在激酶實(shí)驗(yàn)中，TDZD-8對(duì)PKA, PKC, Cdk-1/cyclin B 和 CK-II 沒有抑制效果。 TDZD-8特異性誘導(dǎo)原代白血病細(xì)胞樣本發(fā)生細(xì)胞死亡。TDZD-8可以除去白血病祖細(xì)胞和干細(xì)胞。TDZD-8誘導(dǎo)細(xì)胞死亡，具有極其迅速的細(xì)胞死亡動(dòng)力學(xué)，且細(xì)胞膜完全喪失。TDZD-8作用于原代AML細(xì)胞樣本，抑制PKC和 FLT3。
TDZD-8 (TDZD8, 1?or 2?mg/kg, i.p.) both reduces the induction of p-DARPP32 following chronic L-dopa treatment in parkinsonian animals. TDZD8 treatment of 21 days induces a significant reduction in PKA expression in rats with established dyskinesia. Moreover, TDZD8 reduces FosB mRNA level in the striatum and lowers the expression of PPEB mRNA to similar levels as in 6-OHDA-lesioned rats without treated with L-dopa. The decrease in dyskinesia induced by TDZD8 is overcome by dopamine rceptor-1 agonist.